Abstract:Integrating multiple PI3K conformations, whether through molecular docking or pharmacophore, yields higher prediction accuracy. The naïve Bayesian classification model has the potential to enhance the enrichment of virtual screening. A virtual screening strategy, utilizing multiple protein structures and integrating molecular docking and pharmacophore, is developed to identify novel PI3K inhibitors. The phosphatidylinositol‐3 kinase (PI3K) pathway is a crucial intracellular signaling pathway within living cells. The hyperactivation of PI3K signaling cascades is a common occurrence in human cancers, rendering PI3K a promising therapeutic target. Although several PI3K inhibitors are already available on the market, the adverse side effects of current therapies continue to highlight the necessity for the development of novel PI3K inhibitors. In this study, a virtual screening strategy employing naïve Bayesian classification (NBC) models, based on multicomplex‐based molecular docking and pharmacophore modeling, is developed. First, the docking accuracy and scoring reliability of four docking software are assessed, and Glide demonstrated higher predictability for PI3K inhibitors. Second, pharmacophore models are generated based on the current reported PI3K‐inhibitor interactions, and five pharmacophore hypotheses displayed significant capability in discriminating active PI3K molecules from inactive ones. Subsequently, three NBC models are constructed based on molecular docking and/or pharmacophore models, and the validation results showed that the NBC model, combining multicomplex‐based molecular docking and pharmacophore, significantly improved the hit rate of virtual screening against PI3K. Finally, the optimal NBC model is employed for virtual screening against the ChEMBL database, leading to the identification of multiple molecules with high potential as active PI3K inhibitors.

Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.

Combination Of Pharmacophore Model Development And Binding Mode Analyses: Identification Of Ligand Features Essential For I Kappa B Kinase-Beta (Ikk Beta) Inhibitors And Virtual Screening Based On It

Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.

Novel IKKβ Inhibitors Discovery Based on the Co-Crystal Structure by Using Binding-Conformation-based and Ligand-Based Method.

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Identify promising IKK-β inhibitors: A docking-based 3D-QSAR study combining molecular design and molecular dynamics simulation

The discovery of a novel IκB kinase β inhibitor based on pharmacophore modeling, virtual screening and biological evaluation

Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Developing new PI3Kγ inhibitors by combining pharmacophore modeling, molecular dynamic simulation, molecular docking, fragment-based drug design, and virtual screening

Discovering New PI3Kα Inhibitors with a Strategy of Combining Ligand-Based and Structure-Based Virtual Screening.

Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking

Pharmacophore Models Generation by Catalyst and Phase Consensus-Based Virtual Screening Protocol Against PI3Kα Inhibitors

Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

Virtual Screening of B-Raf Kinase Inhibitors: A Combination of Pharmacophore Modelling, Molecular Docking, 3D-QSAR Model and Binding Free Energy Calculation Studies

Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Discovery of Novel Akt2 Inhibitors.

Integration of Multicomplex‐Based Pharmacophore Modeling and Molecular Docking in Machine Learning‐Based Virtual Screening: Toward the Discovery of Novel PI3K Inhibitors

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors